Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 July 2019 | Story Leonie Bolleurs
Edwin Skhosana
Edwin Skhosana is working hard to become a successful and competent actuary one day. With him is his lecturer, Dr Michael von Maltitz.

Edwin Skhosana, an Actuarial Sciences student, was described by his lecturer, Dr Michael von Maltitz of the Department of Mathematical Statistics and Actuarial Science, as ‘very quiet’ in his Causal Inference class. 

This may sound like a compliment, but it’s not.

For Dr Von Maltitz, being quiet is definitely not encouraged – not with the new teaching methods applied in class.

“See, my class is all about engagement – getting the students to watch videos on the topics, read about the methods in question, and then come to class to grill me about things they don’t understand. This change in teaching method is extremely disconcerting for many Mathematical students, who have up until now only been taught in the ‘memorise-regurgitate’ form they had ever since the start of high school,” he explains.

Future success


“My goal is to get the students to a level of understanding where they can sit down with me or with an expert in the field and have a conversation about the Mathematical Statistics topics that I teach. This is a very difficult task in such a technical module, and few students ever feel comfortable enough to engage with me actively in class in this way,” Dr Von Maltitz points out. 

Edwin is working hard towards applying the skills and knowledge he has obtained at university to become a successful and competent actuary one day. 

An important turning point was when it dawned on him how the things discussed in class could find an important practical application in so many fields.  

“This suddenly drove a spontaneous fascination in my mind that led me to engage with Dr Von Maltitz,” the previously quiet Edwin explains.

And everything changed.

Desperate to learn

Dr Von Maltitz explains: “Edwin came to my office to ask some questions. The incredible thing was that he sat down, and a conversation about the Mathematics, the foundations, and the methods just flowed between us. I have seldom had such an insightful chat about my module with a student. It was like a cascade of information just fell into place for Edwin.”

Although he sometimes still experiences his studies as challenging and grapples to adapt to the various styles of lecturing from different lecturers, Edwin now has hope for his class in Causal Inference. 

“I think Dr Von Maltitz’s way of presenting in class is excellent. It is, however, hard to grasp if you are still anchored in the old way of cramming, because he wants you to understand and be able to apply what he teaches,” says Edwin.

“It was just wonderfully refreshing to see someone so desperate to learn something (rather than just wanting to get a degree), and then actually managing to turn around a bad semester mark into such a river of understanding,” Dr Von Maltitz concludes.

Dr Michael von Maltitz
Dr Micheal von Maltitz

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept